Stem Cell Clinic

Stem Cell Assay Market To Witness Increase In Revenues By 2024 – Montana Ledger

By Stell Cell Research

Overview

The business intelligence report from TMR is an all-important tool that enables vendors to discover growth opportunities, and undertake strategic planning to tap into these opportunities. The valuable facts, figures, and statistical information provided is compiled based on extensive primary and secondary research and insightful inputs received by industry experts.

Market Insights

The market research study from TMR discusses the demand drivers, geographical distribution, and competitive scenario of the Stem Cell Assay Market for the 2016 2024 forecast period. Further, it throws light on growth opportunities and challenges facing the market. The market indicators thus provided are valuable for market participants for business planning, financial modeling, scope of expansion, and investment plan in the market over the forecast period.

The research report provides deep insights into the competitive outlook of theStem Cell Assay Market. The research report looks into growth strategies employed by key players, and how these strategies are poised to change the competitive dynamics in the Market over the forecast period. Further, our research reports include market share estimates and changing hierarchy in the market over the forecast period. The influence of growth strategies on the changing hierarchy in the market is also discussed in this report.

Looking for Regional Analysis or Competitive Landscape in Stem Cell Assay Market , Ask For A Customized Report

The report provides an exhaustive list of top players in the Stem Cell Assay Market: Thermo Fisher Scientific, Merck KGaA, Promega Corporation, STEMCELL Technologies Inc., Bio-Techne Corporation, GE Healthcare, Cellular Dynamics International Inc., Hemogenix, Bio-Rad Laboratories, Inc., and Cell Biolabs Inc.

The regional analysis covers: North America (U.S. and Canada)Latin America (Mexico, Brazil, Peru, Chile, and others)Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)Eastern Europe (Poland and Russia)Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)Middle East and Africa (GCC, Southern Africa, and North Africa)

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market. Important changes in market dynamics market segmentation up to the second or third level. Historical, current, and projected size of the market from the standpoint of both value and volume. Reporting and evaluation of recent industry developments market shares and strategies of key players. Emerging niche segments and regional markets. Objective assessment of the trajectory of the market. Recommendations to companies for strengthening their foothold in the market

Request For Sample Research Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19364

Reasons to Purchase this Research Report

More:
Stem Cell Assay Market To Witness Increase In Revenues By 2024 - Montana Ledger

Physicians’ Education Resource to Host Satellite Symposia at Annual American Society of Hematology Meeting and Exposition in Orlando – Business Wire

By Stell Cell Research

CRANBURY, N.J.--(BUSINESS WIRE)--Physicians Education Resource (PER), a worldwide leading resource for continuing medical education (CME), will conduct five CME-accredited satellite symposia during the 61st American Society of Hematologys Annual Meeting and Exposition. The symposia will take place Friday, Dec. 6 at the Hyatt Regency Orlando and Rosen Centre Hotel in Orlando, Florida.

We are once again thrilled for the opportunity to return to ASHs annual meeting exposition and provide actionable education to hematologists, said Phil Talamo, president of PER. Each symposium this year will offer attendees noteworthy insight on pivotal topics in the realm of hematology, including the primary hemophagocytic lymphohistiocytosis, the graft-versus-host-disease, adolescent and young adult and adult acute lymphoblastic leukemia, myeloproliferative neoplasms, and diffuse large b-cell lymphoma.

The PER satellite symposia are as follows:

About Physicians Education Resource (PER)

Since 1995, PER has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While expanding into topics outside of oncology, PER stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER is a brand of MJH Life Sciences, the largest privately held, independent, full-service medical media company in the U.S. dedicated to delivering trusted health care news across multiple channels.

See the rest here:
Physicians' Education Resource to Host Satellite Symposia at Annual American Society of Hematology Meeting and Exposition in Orlando - Business Wire

Keep Bioethics out of Elementary and High Schools – National Review

By Stell Cell Research

(Mike Blake/Reuters)

Bioethicist Jacob M. Appel wants the bioethics movement to educate your children about the policy and personal conundrums that involve medical care and health public policy. He claims that most of us give little thought to issues that may arise, such as end-of-life care and prenatal screening. Then, when an issue arises, people are unprepared to make wise and informed decisions. From, The Silent Crisis of Bioethics Illiteracy, published in Scientific American:

Change will only occur when bioethics is broadly incorporated into school curricula [at an early age] and when our nations thought leaders begin to place emphasis on the importance of reflecting meaningfully in advance upon these issues

Often merely recognizing such issues in advance is winning the greater part of the battle. Just as we teach calculus and poetry while recognizing that most students are unlikely to become mathematicians or bards, bioethics education offers a versatile skill set that can be applied to issues well outside the scientific arena. At present, bioethics is taught sporadically at various levels, but not with frequency, and even obtaining comprehensive data on its prevalence is daunting.

Is this really an appropriate field for children? Consider the issues with which bioethics grapples and whether elementary-, middle-, and high-school children have the maturity to grapple with them in a meaningful and deliberative way (not to mention, the acute potential that teachers will push their students in particular ideological directions):

Even if some students are mature enough to grapple with these issues thoughtfully, the next problem is that bioethics is extremely contentious and wholly subjective. Its not science, but focuses on questions of philosophy, morality, ideology, religion, etc.. Moreover, there is a dominant point-of-view among the most prominent voices in the field e.g., those who teach at leading universities and would presumably be tasked with writing the educational texts. These perspectives would unquestionably often stand in opposition to the moral values taught young students by their parents.

Appel is typical of the genus (if you will). He has called for paying women who plan to abort to gestate longer in their pregnancy so that more dead fetuses will be available sufficiently developed to be harvested for organs and used in experiments. He advocates mandatory termination of care for patients who are diagnosed as persistently unconscious to save resources for what he considers more important uses. He has also supported assisted suicide for the mentally ill.

Appels perspectives are not unique in bioethics. The movement went semi-berserk when President George W. Bush appointed the conservative bioethicist Leon Kass to head the Presidents Council on Bioethics one even called him an assassin for opposing human cloning research as many worked overtime to discredit the Councils work in the media.

Indeed, activists without a modifier like Catholic or pro-life before the term bioethicistare overwhelmingly very liberal politically and intensely secular in their approach. Most support an almost unlimited right to abortion, the legalization of assisted suicide, genetic engineering (once safe), and accept distinguishing between human beings and persons, that is, they deny universal human equality.

Some wish to repeal the dead donor rule that requires organ donors to be dead before their body parts are extracted an idea that admittedly remains somewhat controversial in the field. Most mainstream bioethicists deny the sanctity of human life and many think that an animal with a greater cognitive capacity has greater value than a human being with lower cognition. Add in the sectors general utilitarianish approach to health-care issues, such as supporting rationing, and the potential for propagandizing becomes clear.

With such opinions, often passionately held, how long would it be before early bioethics education devolved into rank proselytizing? But Wesley, Appel might say. the classes would be objective! Every side would be given equal and a respectful and accurate presentation.

Sure. If you believe that, you must think current sex education curricula and high school classes in social justice present all sides of those issues dispassionately and without attempt to persuade the students to particular points of view and cultural perspectives.

I have a deal for Appel: In-depth courses in bioethics should not be taught before college unless I get to write the textbooks! I promise to be objective and fairly present all sides. Honest!

Do you think he and his mainstream colleagues would approve of that deal?

Neither do I. And we shouldnt go along with his idea for the very same reason.

See the original post here:
Keep Bioethics out of Elementary and High Schools - National Review

Stem Cell Cartilage Regeneration Market 2019, Trend, CAGR Status, Growth, Analysis and Forecast to 2025 – Virtualnewsusa

By Stell Cell Research

The Global Stem Cell Cartilage Regeneration Market 2019-2024 report gives an overview of the relevant market including analysis, latest market trends and developments including features, technology and market chain types, applications and top manufacturers. Stem Cell Cartilage Regeneration market research report also gives an analysis of the key players along with upcoming industry supply, market demand, price, competition and industry forecast from 2019 to 2024. The report is the opinion of industry experts and gives an overview of the past. Year and current market condition.

Sample report can be viewed in a PDF form by visiting @ researchunt.com/report/global-stem-cell-cartilage-regeneration-market-research-report-2019-2025/#Free-Sample-Report

The global Stem Cell Cartilage Regeneration market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

Stem Cell Cartilage Regeneration Market Segment by Manufacturers include:

Stem Cell Cartilage Regeneration Market Segment by Regions includes:

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America, Middle East and Africa

By Types, the Stem Cell Cartilage Regeneration Market can be Split into:

Cell Based Approaches

Non-cell Based Approaches

By Applications, the Stem Cell Cartilage Regeneration Market can be Split into:

Read Detailed Index of full Research Study at @ researchunt.com/report/global-stem-cell-cartilage-regeneration-market-research-report-2019-2025/

Report Objectives:

Browse Detailed TOC, Tables, Figures, Charts And Companies Mentioned In Stem Cell Cartilage Regeneration Market Research Report [emailprotected] researchunt.com/report/global-stem-cell-cartilage-regeneration-market-research-report-2019-2025/#Buying-Enquiry

Request customized copy of Stem Cell Cartilage Regeneration report:

If you wish to find more details of the report or want customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us @ [emailprotected]

Read this article:
Stem Cell Cartilage Regeneration Market 2019, Trend, CAGR Status, Growth, Analysis and Forecast to 2025 - Virtualnewsusa

The Bold and the Beautiful Star Don Diamont Supports ALS Research – Soap Hub

By Stell Cell Research

As a member of the daytime community for many years, Don Diamont has seen soaps tackle important social issues. Now, the star of The Bold and the Beautiful is lending his name to a topical and vital concern.

The actor was invited recently to speak at the annual ISSCR (International Society for Stem Cell Research Conference) in Los Angeles. He accepted to show his support for a dear pal, who is battling ALS.

I was touched, and humbled to be asked to speak for, and about my beloved friend Nanci Ryder at this years ISSCR Conference, Diamont posted on his Instagram account. The event is the largest gathering of stem cell scientists and clinicians in the world. Nancis story is a powerful one, and I was honored to have an opportunity to share it with those on the front lines in the battle to find a cure for ALS.

Yesterday, at The Walk to Defeat ALS, I was with Nanci and the group of wonderful souls that make up TEAM NANCI, Diamont continued. Thank you to the @alsagoldenwest chapter for all that you do! Thank you to Dr. Justin Ichida! Justin is the Assistant Professor of Stem Cell and Regenerative Medicine at the Keck School of Medicine USC. Hes making significant strides in moving toward a cure for ALS. Finally, to anybody out there whos helping in any way to fight the good fight in eliminating this horrible illness, thank you!

Diamont concluded his post with words of encouragement for his friend: Nanci, you are the bravest of the brave! I, and we LOVE YOU

Soap fans may recall that the late Michael Zaslow (ex-Roger, Guiding Light; ex-David, One Life to Live) had been diagnosed with the disease. He passed away in 1998. For more information on ALS, click here. The Bold and the Beautiful airs weekdays on CBS. Check local listings for air times.

View this post on Instagram

I was touched, and humbled to be asked to speak for, and about my beloved friend Nanci Ryder at this years ISSCR Conference. The event is the largest gathering of stem cell scientists and clinicians in the world. Nancis story is a powerful one, and I was honored to have an opportunity to share it with those on the front lines in the battle to find a cure for ALS. Yesterday, at The Walk to Defeat ALS, I was with Nanci and the group of wonderful souls that make up TEAM NANCI. Thank you to the @alsagoldenwest chapter for all that you do! Thank you to Dr. Justin Ichida! Justin is the Assistant Professor of Stem Cell and Regenerative Medicine at the Keck School of Medicine USC. Hes making significant strides in moving toward a cure for ALS. Finally, to anybody out there whos helping in anyway to fight the good fight in eliminating this horrible illness, thank you! Nanci, you are the bravest of the brave! I, and we LOVE YOU

A post shared by Don Diamont (@dondiamont) on Nov 4, 2019 at 4:15pm PST

03:31

Dollar Bill Tribute

Video Credit: SunRiseIta

See the original post:
The Bold and the Beautiful Star Don Diamont Supports ALS Research - Soap Hub

Human heart cells change during spaceflight, say scientists in study that could have far-reaching effects on c – MEAWW

By Induced Pluripotent Stem Cells

Human heart cells are changed by spaceflight but return to mostly normal on Earth, according to a study that examined how the human heart functions in spaceflight. The scientists were surprised as to how quickly human heart muscle cells could adapt to the environment in which they are placed.

The research team examined the cell-level cardiac function and gene expression in human heart cells that were cultured aboard the International Space Station (ISS) for 5.5 weeks. They found that heart muscle cells -- derived from stem cells -- adapted well to their environment during and after spaceflight.

The analysis, says the team, shows that exposure to microgravity altered the expression of thousands of genes, but largely normal patterns of gene expression reappeared within 10 days after returning to Earth.

These findings provide insight into how the human heart functions at the cellular level in spaceflight. This study suggests that the human heart muscle cells are very adaptable to the environment in which they are placed, including microgravity. Microgravity is an environment that is not very well understood in terms of its overall effect on the human body, and studies like this will be able to help shed light on how the cells of the body behave in space," Dr. Joseph C. Wu, Director, Stanford Cardiovascular Institute at Stanford University School of Medicine, told MEA WorldWide (MEAWW).

The researchers explain that human heart muscle cells, like the whole heart, change their functional properties in spaceflight and compensate for the apparent loss of gravity by changing their gene expression patterns at the cellular level.

"This study does not tell us how the heart as a whole changes in microgravity. There are several other types of cells in the heart that were not included in this study. We also do not know how the cells might react if they were exposed to microgravity for a longer period of time. However, these are both things we can test in the future. The results we observed in this study will allow us to focus those future studies on characteristics of the heart muscle cells we know are strongly affected by microgravity," Dr. Wu told MEAWW.

With extended stays aboard the ISS becoming commonplace, there is a need to better understand the effects of microgravity on cardiac function, say experts. Past studies have shown that spaceflight induces physiological changes in cardiac function. Astronauts on space shuttle missions have experienced reduced heart rate, lowered arterial pressure, and increased cardiac output. But to date, most cardiovascular microgravity physiology studies have been conducted either in non-human models or at tissue, organ, or systemic levels, says the team.

"The National Aeronautics and Space Administration [NASA] Twin Study demonstrated that long-term exposure to microgravity reduces mean arterial pressure and increases cardiac output. However, little is known about the role of microgravity in influencing human cardiac function at the cellular level," says the study published in 'Stem Cell Reports'.

Accordingly, the research team used human induced pluripotent stem cells to study the effects of spaceflight on human heart function.

"We studied human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). We generated hiPSC lines from three individuals by reprogramming blood cells and then differentiated them into hiPSC-CMs," says the study.

Dr. Wu explains that human induced pluripotent stem cells (hiPSCs) are stem cells that can be produced from a small sample of blood or skin through a process called "reprogamming".

"These hiPSCs can be then turned into almost any cell type of interest, including beating human heart muscle cells, or cardiomyocytes. Since these hiPSC-derived cardiomyocytes mimic the function of true adult human heart cells, we can use them as a model for how the cells of the human heart respond to microgravity," Dr. Wu told MEAWW.

Beating hiPSC-CMs were launched to the International Space Station aboard a SpaceX spacecraft, as part of a commercial resupply service mission. Simultaneously, ground control hiPSC-CMs were cultured on Earth for comparison.

"Upon return to Earth, space-flown hiPSC-CMs showed normal structure and morphology. However, they did adapt by modifying their beating patterns and calcium recycling patterns," the findings state.

The researchers performed RNA sequencing. "These results showed that 2,635 genes were differentially expressed among flight, post-flight, and ground control samples. A comparison of the samples revealed that hiPSC-CMs adopt a unique gene expression pattern during spaceflight, which reverts to one that is similar to groundside controls upon return to normal gravity," says the study.

The findings, according to the researchers, could provide insight into cellular mechanisms that could benefit astronaut health during long-duration spaceflight, or potentially lay the foundation for new insights into improving heart health on Earth.

"We know that humans can spend months and years in space. Through decades of analyses, we know that the human heart as a whole organ changes its shape, size, and function in spaceflight. These changes are one reason why astronauts must exercise in space for hours every day to keep their heart muscles strong. While our cell-based experiments were able to confirm that changes also occur on the cellular level, we cannot directly translate this to the organ-level without further studies. The changes in our hiPSC-cardiomyocytes are not adverse effects, but rather adaptations to microgravity. The changes reflect how the cells of the human body can quickly adapt to a low gravity environment," Dr. Wu told MEAWW.

The research team now plans to test different treatments on the human heart cells to determine if they can prevent some of the changes the heart cells undergo during spaceflight.

Visit link:
Human heart cells change during spaceflight, say scientists in study that could have far-reaching effects on c - MEAWW

Here’s Why Fate Therapeutics Dropped as Much as 19.9% Today – Motley Fool

By Induced Pluripotent Stem Cells

What happened

Shares of Fate Therapeutics (NASDAQ:FATE) fell nearly 20% today after the company reported third-quarter 2019 operating results and announced it will make six presentations at the upcoming American Society of Hematology (ASH) annual meeting in December. The biopharma disclosed several notable updates and is clearly making progress, but there are certainly a lot of moving parts for investors to understand.

Fate Therapeutics became the first entity to dose a patient with an engineered stem cell-derived cellular medicine in October, began enrolling a higher-dose cohort for a separate drug candidate, announced a new manufacturing facility, and presented several more updates. Therefore, it appears that today's sell-off is an attempt to buy time to digest the sudden increase in complexity, especially considering management decided to hold off important details until the ASH presentations next month.

As of 2:22 p.m. EST, the small-cap stock had settled to a 9.4% loss.

Image source: Getty Images.

Fate Therapeutics was one of the first companies to jump into developing natural killer (NK) cells as therapeutic agents. NK cells offer several notable advantages compared to T cells, the first immune cells to be widely studied in immuno-oncology, including the ability to dose patients multiple times. But they've largely failed to live up to the hype in early clinical studies.

The company is hoping its unique approach can lead to success. Rather than engineering each individual patient's own NK cells, Fate Therapeutics is using a single master cell line -- an induced pluripotent stem cell (iPSC) line -- to engineer cellular medicines that can be given to any individual. That should smooth over manufacturing obstacles, lower costs, and potentially lead to more reproducible outcomes compared to the initial approach used in CAR-T cell therapies.

But there's a lot to digest as the pipeline matures. Fate Therapeutics announced clinical progress for three drug candidates, explained a highly complex phase 1 clinical trial for FT500 in advanced solid tumors, and opened a new manufacturing facility. To the dismay of Wall Street analysts, executives provided few specific details of drug candidates on the third-quarter 2019 earnings conference call and instead chose to wait until the updates at ASH next month.

Investors interested in Fate Therapeutics shouldn't necessarily be discouraged by any recent developments. The company's technology platform ultimately will be judged by clinical results. Given the lack of specific details and a sudden increase in complexity and competition -- including a partnership between Allogene and Notch Therapeutics yesterday and recent fundraising rounds by A2 Biotherapeutics, Nkarta Therapeutics, and Achilles Therapeutics -- Wall Street simply took the "show me" approach. Analysts may get their answers in December.

Read the original here:
Here's Why Fate Therapeutics Dropped as Much as 19.9% Today - Motley Fool

Space travel may change the human heart – Inverse

By Induced Pluripotent Stem Cells

Spending time in the microgravity environment aboard the International Space Station appears to alter gene expression in the human heart. The results shed light on what life in space might do to the human body and what happens when that body returns to Earth.

Humans have been venturing out into space for over 50 years now, but very little is known about the toll microgravity might take on the human body. With the age of commercial space travel fast approaching, it is increasingly critical to understand how our bodies adapt to space flight.

Space is our next frontier. In the next 100 years, humans will be traveling through space all the time, says Joseph Wu, Stanford University professor and senior author on the study.

To understand the effect of space travel on our most crucial, blood-pumping organ, in 2016 Wus team sent beating, human-induced pluripotent stem cell-derived cardiomyocytes, a kind of heart muscle cell, to the International Space Station.

The results, published in the journal Stem Cell Reports, show that time in a microgravity environment alters gene expression in the heart muscle cells, but most of these changes revert after the cells are back on Earth.

This is the first study to look at the effects of microgravity on a cellular level, the researchers say.

To create the stem-cell model, the researchers harvested blood cells from three people, none of whom had a history of heart disease. They then reprogrammed the cells to become cardiomyocytes. The cells were sent to the ISS and cultured aboard, staying in the microgravity environment for a total of five and a half weeks before being flown home.

By comparing the cells gene expression in-space, on return and to controls, the researchers found that time in space altered the expression patterns in 2,635 of the cells genes. Most of the altered genes are related to mitochondrial metabolism, the process by which nutrients are converted into energy and used to carry out different functions in cells. Expression patterns looked similar to controls after 10 days back on Earth a possible sign that the body can reverse adaptations to life in space.

We do know that heart muscle cells can adapt. Its hard to tell if these changes are necessarily negative or if they are natural adaptations, says Alexa Wnorowski, a graduate student at Stanford University who was involved in the study.

Its hard for us to come up with a conclusion of what that means. It gives us a future direction to look into, she says.

The team plans to use the data and compare it with both records of physiological changes in astronauts during missions and with symptoms of heart disease in order to get a better sense of these adaptations long-term effects.

The study could also have implications on heart health for those that dont even plan to travel beyond the stars, say the researchers, offering insight into how the environment may affect gene expression in heart cells here on Earth.

Thats one of the hopes for the directions that this type of research might go, Wnorowski tells Inverse. If we figure out that microgravity is able to replicate some of the gene expressions we see in diseases on Earth.

View original post here:
Space travel may change the human heart - Inverse

Burning in knee: 7 causes and how to treat them – Medical News Today

By Platelet Rich Plasma Injections

Knee joints are under a lot of physical stress each day. It is very common to experience pain in one or both knees due to normal wear and tear, physical activity, or injury. Often, if a person has a knee injury or strain, the pain can feel as though it is burning.

Burning knee pain can occur in many places in the knee. For many people, the fronts and backs of the knees are the most common spots to feel a burning sensation. Sometimes, however, the sides of the knees can also feel as though they are burning.

A burning sensation in any part of the knee typically indicates that there is a larger problem that may require investigation and treatment.

This article explores some common causes of burning pain in the knee, the typical treatments for them, and when to see a doctor.

The location of the burning knee pain can often give some clues as to what is causing it. The sections below list some causes of location-specific knee pain.

Burning pain in the front of the knee is often due to injuries such as:

If a person has burning pain on the side of the knee, it could be due to iliotibial band syndrome or pes anserine bursitis.

Burning pain behind the knee may be due to:

The following sections detail some potential causes of burning knee pain and how to treat them.

Knee cartilage, or meniscus, helps cushion the joint during physical activities such as walking, running, and jumping. If a person sustains a blunt force injury to this area or twists it forcefully, it can tear the knee cartilage. This is painful and can feel like burning.

There are various treatment options for a knee cartilage tear. Often, the first steps in treatment involve taking pain relief drugs such as ibuprofen and trying muscle strengthening workouts.

If the knee cartilage does not improve, a doctor or healthcare team may recommend steroid injections in the knee or surgical options such as:

Knee ligament tears often occur due to blunt force trauma to the outside of the knee. People who play hockey, football, or other contact sports are at greater risk of tearing or pulling their knee ligaments.

Health professionals often classify ligament tears by how severe they are. A partial tear may require less treatment than a severe tear. Some treatment options for partial tears include:

If the tear is very severe or does not improve, a doctor may recommend surgical options.

Runner's knee, also known as chondromalacia, occurs as a result of overuse of the knee joint. It is particularly common among runners and other people who put consistent pressure and stress on their knees.

Chondromalacia occurs when the knee cartilage deteriorates, providing less cushioning to the joint.

The first steps in treatment often involve therapies to help reduce pain and swelling and allow the knee to heal. Some treatments include:

If the knee does not improve, a healthcare team may recommend arthroscopic surgery. This involves smoothing the cartilage to allow it to heal better.

Osteoarthritis is the most common form of arthritis in the United States. In fact, around 30.8 million people now live with the condition.

Osteoarthritis can affect nearly any joint, but it is most common in the hands, hips, spine, and knees.

Osteoarthritis is characterized by the wearing down of the protective cartilage in the joints. It is not possible to reverse osteoarthritis, so it may eventually require a joint replacement.

Some common treatments for osteoarthritis include:

Patellar tendinitis is an overuse injury of the tendon that connects the kneecap to the shin. It can cause burning and pain in the front of the knee.

There are several potential treatment steps a person can take to treat patellar tendinitis, including:

If these therapies do not work, a doctor may recommend more invasive therapies, such as a platelet-rich plasma injection or oscillating needle procedure.

Iliotibial band syndrome (ITBS) often affects runners. It occurs when the connective tissue along the length of the thigh rubs against the outside of the knee during running and other physical activities.

ITBS can feel like burning when the band rubs against the side of the knee.

There is no formal treatment for ITBS. However, people with this condition often take some of the following steps:

PFPS occurs in the front of the knee. It often starts as mild pain and gradually builds up. It can occur in one or both knees. It is usually worse during physical activities.

Some general treatment options for PFPS include:

In more severe cases, a doctor may recommend arthroscopic surgery, which involves removing and smoothing damaged cartilage.

In some cases, a person may receive treatment shortly after sustaining a knee injury. In others, a person may first try to deal with the pain they experience, only seeing their doctor when it becomes severe.

For overuse injuries, the best solution is often to rest, apply an ice pack, and focus on muscle building activities that do not put strain on the knees. However, if the pain continues to build despite resting, a person should talk to their doctor about their symptoms.

They may be able to recommend additional therapies, such as physical or occupational therapy. In severe cases, they may even recommend surgical options.

Several things can give rise to burning knee pain. Some injuries are acute and can start causing pain immediately, while others are overuse-related and will build up gradually.

In many cases, taking OTC pain relievers, applying an ice pack, and resting are enough to help prevent further injury and pain. If the pain does not go away or gets worse, however, a doctor may suggest surgery or more invasive treatment options.

Read the original:
Burning in knee: 7 causes and how to treat them - Medical News Today

Joint Pain Injections Market to Expand at a Positive CAGR, Rising Support from Government in Research Activities to Boost the Market – News Reel Hub

By Platelet Rich Plasma Injections

Joint Pain Injections Market summarizes details y key players are Anika, Therapeutics, Inc., Teva Pharmaceuticals Industries Ltd.Flexion Therapeutics Inc., Pfizer Inc., Reddys Laboratories Ltd., Zimmer Biomet, Bioventus, SEIKAGAKU CORPORATION and more

The information is shared by Fortune Business Insights, in a report, titled Joint Pain Injections Market Size, Share and Global Trend By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet-Rich Plasma Injections, Others (Placental Tissue Matrix Injections, etc), By Joint Type (Knee and Ankle, Hip, Shoulder and Elbow, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026.

CDC reports that every year approximately 15 million people in the U.S. face severe joint pain because of arthritis. The rising prevalence of arthritis can increase the demand for treatments, which in turn, will propel the growth of the global joint pain injections market.

Browse Complete Report Details at

https://www.fortunebusinessinsights.com/industry-reports/joint-pain-injections-market-100871

Some of the other players functioning in the global market are

One of the most common types of arthritis is osteoarthritis which primarily affects hands and feet. Some of the major causes associated with osteoarthritis are the rising prevalence of obesity, increasing aging population, zero physical activity, and mineral bone density loss. Injections such as hyaluronic acid and corticosteroid are extensively used to reduce pain and inflammation in affected areas.

Joint pains are more prevalent in the elderly population. As per research studies, injections such as platelet-rich plasma and placental tissue matrix have proved to be effective in the reduction of pain and inflammation. Furthermore, these infections will substantially reduce the risk of infection on the affected joint in the aged population. Driven by such factors, the joint pain injections market growth is likely to increase in the forthcoming years.

Get Sample PDF Brochure at

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/joint-pain-injections-market-100871

Surging Research Investments to Give Significant Boost to the Market in North America

According to Arthritis Foundation, around 54 million people in the people suffer from arthritis and it is estimated that over 78 million people will be affected by this disease by 2040. This shows that the demand for joint pain medicine is likely to increase in the U.S., which drives the market in North America. As per the report, North America is anticipated to maintain its dominance in the global joint pain infections market through the forecast years.

The growth is primarily attributable to the increasing prevalence of joint disorders. People in this region are increasingly becoming aware of joint pain infections treatment. Not only this, leading players are making huge investments in research activities, which will eventually drive the market in North America.

Several treatments such as knee arthritis viscosis supplementation received FDA approval, which contributes to the growth of the market in this region. Following North America, Europe is also expected to grow at a considerable rate in the forecast period.

The market in Asia Pacific is expected to witness considerable growth owing to the rising prevalence of joint disorders and patient pool. Several government organizations are conducting awareness programs on different types of arthritis treatments available in the region. This will enhance the quality of life for such patients and augment demand for joint pain injections. Influenced by these factors, the joint pain infections market size is estimated to grow over the projected horizon.

Segmentation for Joint Pain Injections Market

By Product

By Joint Type

By Distribution Channel

By Geography

Speak To Analyst at

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/joint-pain-injections-market-100871

SYNOJOYNTReceives FDA Approval to Teva Pharmaceuticals for Treating Osteoarthritis Patients

Joint pain injections are available for different joints which include hip, knee and ankle, shoulder and elbow. Of these, knee and ankle joints hold the largest share in the global market. This will surge the joint pain injections market size in the forthcoming years. These injections effectively reduce inflammation and pain in knees, thus increasing their demand.

The demand for cost-effective treatments is increasing and the rising prevalence of osteoarthritis are driving the joint pain injections market, stated a lead analyst at Fortune Business Insights. These, coupled with rising technological advancements in healthcare, are likely to uplift the market growth. Several companies are introducing new products to strengthen their market position.

SYNOJOYNT, a joint pain injection receives FDA approval on marketing this product. The injection was introduced by TEVA Pharmaceuticals in May 2018 for patients suffering from osteoarthritis. Zimmer Biomet develops a new joint pain injection containing hydraulic acid called Gel-One Hyaluronate. The injection received FDA approval in February 2017 and is used to treat patients with knee osteoarthritis.

STRONG INDUSTRY FOCUS:

View Related Report at

Europe Compression Bandages Market to Witness a Healthy CAGR of 5.2%; Advent of Efficient Pressure Bandages to Provide Impetus

Why the Medical Lasers Market is set to explode? Top Companies: El.En. S.p.A., Lumenis, Fotona, Ellex Medical Lasers Ltd., BIOLASE, Inc., Sisram Medical Ltd. And more

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: [emailprotected]

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Joint Pain Injections Market to Expand at a Positive CAGR, Rising Support from Government in Research Activities to Boost the Market

More here:
Joint Pain Injections Market to Expand at a Positive CAGR, Rising Support from Government in Research Activities to Boost the Market - News Reel Hub

→←